ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,346.99
-0.11%
Dow Jones
38,798.99
-0.22%
US Dollar vs MXN
18.4136
0.00%
Brent Oil
79.395
0.00%
Bitcoin
69,506.33
0.25%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Sarepta Therapeutics Inc New (SRPT)

  7. Sarepta Therapeutics Inc New (SRPT) Noticias

SRPT

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics Inc New
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SRPT
FechaHoraFuenteTítuloSímboloCompañía
07/06/202415:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SRPTSarepta Therapeutics Inc New
07/06/202412:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SRPTSarepta Therapeutics Inc New
31/05/202416:45Business WireSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SRPTSarepta Therapeutics Inc New
29/05/202416:48PR Newswire (US)Sarepta Therapeutics Set to Join S&P MidCap 400NASDAQ:SRPTSarepta Therapeutics Inc New
06/05/202419:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SRPTSarepta Therapeutics Inc New
06/05/202419:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SRPTSarepta Therapeutics Inc New
03/05/202409:07Business WireGene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global HealthNASDAQ:SRPTSarepta Therapeutics Inc New
01/05/202415:05Business WireSarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:SRPTSarepta Therapeutics Inc New
24/04/202407:30Business WireSarepta Therapeutics to Announce First Quarter 2024 Financial ResultsNASDAQ:SRPTSarepta Therapeutics Inc New
08/03/202416:38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SRPTSarepta Therapeutics Inc New
04/03/202407:30Business WireSarepta Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:SRPTSarepta Therapeutics Inc New
29/02/202408:00Business WireSarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship ProgramNASDAQ:SRPTSarepta Therapeutics Inc New
28/02/202415:05Business WireSarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:SRPTSarepta Therapeutics Inc New
21/02/202407:30Business WireSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:SRPTSarepta Therapeutics Inc New
16/02/202406:00Business WireSarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS IndicationNASDAQ:SRPTSarepta Therapeutics Inc New
09/02/202417:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SRPTSarepta Therapeutics Inc New
29/01/202406:00Business WireSarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51NASDAQ:SRPTSarepta Therapeutics Inc New
16/01/202408:02Business WireSarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4NASDAQ:SRPTSarepta Therapeutics Inc New
08/01/202410:55Business WireSarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product RevenueNASDAQ:SRPTSarepta Therapeutics Inc New
02/01/202407:30Business WireSarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SRPTSarepta Therapeutics Inc New
22/12/202307:00Business WireSarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory StatusNASDAQ:SRPTSarepta Therapeutics Inc New
02/11/202307:30Business WireSarepta Therapeutics to Present at the UBS Biopharma ConferenceNASDAQ:SRPTSarepta Therapeutics Inc New
01/11/202315:05Business WireSarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:SRPTSarepta Therapeutics Inc New
01/11/202315:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SRPTSarepta Therapeutics Inc New
31/10/202316:30KR Market News연준 결정 앞두고 뉴욕 증시 상승; 투자자들은 실적 주목NASDAQ:SRPTSarepta Therapeutics Inc New
30/10/202316:17Dow Jones NewsSarepta Therapeutics to Request Expansion of Elevidys to All Age Groups Following Study ResultsNASDAQ:SRPTSarepta Therapeutics Inc New
30/10/202315:01Business WireSarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular DystrophyNASDAQ:SRPTSarepta Therapeutics Inc New
25/10/202307:30Business WireSarepta Therapeutics to Announce Third Quarter 2023 Financial ResultsNASDAQ:SRPTSarepta Therapeutics Inc New
07/09/202308:00Business WireSarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic YearNASDAQ:SRPTSarepta Therapeutics Inc New
05/09/202307:30Business WireSarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:SRPTSarepta Therapeutics Inc New
 Showing the most relevant articles for your search:NASDAQ:SRPT

Su Consulta Reciente

BMF
DIIN24J25
DIIN24J25 - 07/2024
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados